STOCK TITAN

Unicycive Therapeutics, Inc. - $UNCY STOCK NEWS

Welcome to our dedicated page for Unicycive Therapeutics news (Ticker: $UNCY), a resource for investors and traders seeking the latest updates and insights on Unicycive Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Unicycive Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Unicycive Therapeutics's position in the market.

Rhea-AI Summary
Unicycive Therapeutics, Inc. (UNCY) will have its CEO present a company update at a healthcare conference. The webcast will be available for three months on the Unicycive website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
conferences
-
Rhea-AI Summary
Unicycive Therapeutics, Inc. (UNCY) announces financial results for 2023, highlights progress in clinical development programs OLC and UNI-494. OLC topline data expected in Q2 2024, UNI-494 granted orphan drug designation for delayed graft function in acute kidney injury.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
-
Rhea-AI Summary
Unicycive Therapeutics, Inc. (UNCY) announces multiple presentations on product candidates at the 61st European Renal Association Congress. The presentations will cover oxylanthanum carbonate (OLC) and UNI-494, focusing on preclinical data and ongoing clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
none
Rhea-AI Summary
Unicycive Therapeutics, Inc. announces a private placement of 50,000 shares of Series B Convertible Preferred Stock at $1,000 per share, totaling $50 million. The financing, led by Octagon Capital and Great Point Partners, LLC, aims to support clinical development programs for kidney disease therapies, notably Oxylanthanum Carbonate (OLC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
none
-
Rhea-AI Summary
Unicycive Therapeutics, Inc. (UNCY) reports positive preclinical results for UNI-494 in Delayed Graft Function of Acute Kidney Injury. Phase 1 Single Ascending Dose portion of the clinical trial is complete, showcasing promising developments in kidney disease therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
none
-
Rhea-AI Summary
Unicycive Therapeutics, Inc. completes enrollment in pivotal clinical trial for Oxylanthanum Carbonate to treat hyperphosphatemia in CKD patients. Topline data expected in Q2, 2024 with a plan to file NDA thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
Rhea-AI Summary
Unicycive Therapeutics, Inc. (UNCY) receives orphan drug designation from the FDA for UNI-494, a cytoprotective agent to prevent Delayed Graft Function (DGF) in kidney transplant patients. The designation may provide tax credits, fee exemptions, and market exclusivity. UNI-494's mechanism of action shows promise in addressing this serious complication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.88%
Tags
-
Rhea-AI Summary
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) will present new data on the bioequivalence study for its lead product candidate, oxylanthanum carbonate (OLC), at the National Kidney Foundation Spring Clinical Meeting. The Company aims to address patient non-compliance issues with phosphate binders through survey results, contributing to the healthcare community's knowledge on kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.48%
Tags
conferences
-
Rhea-AI Summary
Unicycive Therapeutics, Inc. (UNCY) announced new preclinical data on UNI-494, a clinical-stage biotechnology company developing therapies for patients with kidney disease. The data will be presented at the 29th International Conference on Advances in Critical Care Nephrology AKI and CRRT 2024 in San Diego, CA, showcasing the efficacy of UNI-494 in animal models of delayed graft function and describing the ongoing Phase 1 clinical trial design for UNI-494 in healthy volunteers. The company's primary focus remains on advancing its lead drug, OLC, towards a New Drug Application submission.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.43%
Tags
none
Rhea-AI Summary
Unicycive Therapeutics, Inc. (UNCY) issues a letter to shareholders, highlighting the progress made in its clinical programs, especially with the lead program OLC, a next-generation lanthanum-based phosphate binding agent. The company expects to report topline data from the pivotal clinical trial for OLC in Q2 2024, targeting the multibillion-dollar hyperphosphatemia market. Additionally, the company continues to advance its second compound UNI-494 for the treatment of acute kidney injury and chronic kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.29%
Tags
none
Unicycive Therapeutics, Inc.

Nasdaq:UNCY

UNCY Rankings

UNCY Stock Data

38.93M
13.74M
18.4%
49.18%
0.74%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
LOS ALTOS

About UNCY

unicycive therapeutics is passionate about treating kidney diseases with significant unmet medical needs.